When Andrew Adamovich began investing in biotech companies two decades ago, he never expected to find himself running one.
But when he heard about global heath giant Novartis buying biotech Endocyte in 2018 to access an experimental radio-pharmaceutical drug, his interest was piqued.
Yolanda RedrupRich List editorYolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
